HR-positive breast cancer

April 5, 2019

Faslodex-Arimidex Improves Survival in Post-menopausal Women with Advanced BC, Trial Shows

News

First-line treatment with Arimidex (anastrozole) plus Faslodex (fulvestrant) prolongs the lives of post-menopausal women with hormone receptor (HR)-positive advanced breast cancer, particularly those who have never taken tamoxifen, results of ... Read more

November 5, 2018

Ibrance-Faslodex Combo Improves Survival of Advanced Breast Cancer Patients, Phase 3 Trial Shows

News

Adding Pfizer’s Ibrance (palbociclib) to standard treatment Faslodex (fulvestrant) significantly extended the survival of advanced breast cancer patients in a Phase 3 clinical trial, researchers report. Called PALOMA-3, the trial (NCT01942135) specifically ... Read more

June 8, 2018

New Immunotherapy Rid Patient of Cancer in Breast, Everywhere Else, Study Reports

News

A new immunotherapy method that targets a patient’s tumor cell mutations led to a complete and lasting regression of breast cancer in a woman who had failed all other treatments, a ... Read more

May 11, 2017May 11, 2017

FDA Approves Kisqali Femara Co-Pack to Treat Subset of Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has approved Novartis Oncology‘s Kisqali Femara Co-Pack for to treat postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. The Co-Pack, which includes Kisqali ... Read more

April 26, 2017April 26, 2017

Abemaciclib Combo Seen to Slow Progression in Phase 3 Advanced Breast Cancer Trial

News

An interim analysis from the Phase 3 trial known as MONARCH 3 showed that adding abemaciclib to an aromatase inhibitor — Femara (letrozole) or Arimidex (anastrozole) — helped to treat certain postmenopausal women ... Read more

February 24, 2017February 24, 2017

Early-stage Patients at Intermediate Risk of Cancer’s Return Can Safely Skip Chemotherapy, Study Suggests

News

Women with early stage breast cancer that is hormone receptor-positive, HER2-negative, and lymph node-negative, but who — based on a 21-gene expression assay — are thought to be at intermediate ... Read more

June 15, 2016June 15, 2016

Phase 3 Drug Trial for Advanced Breast Cancer by AstraZeneca Shows Good Results in First-line Treatment

News

AstraZeneca has revealed positive data from its FALCON Phase 3 clinical trial for metastatic breast cancer. More specicically, the trial evaluated Faslodex (fulvestrant) versus Arimidex (anastrozole) as a treatment option for metastatic or locally-advanced breast cancer, ... Read more